Cuprina Holdings Unveils New IVF Media Production Facility
Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) has made a significant enhancement in the field of reproductive health technology with the recent completion of its IVF media production facility in Singapore. This facility marks a collaborative achievement with Ferti-Craft Pte Ltd., a medtech company also based in Singapore. Together, they are poised to meet the growing demands for in-vitro fertilization (IVF) solutions.
ISO Certification and Dealer License Achieved
On April 6, 2025, Cuprina announced that it had achieved ISO 13485 certification, a standard crucial for medical device manufacturing. This certification, awarded by the United Kingdom Accreditation Service (UKAS), affirms that the quality management system at the facility adheres to international regulatory standards. Additionally, the facility has secured a dealer license from the Singapore Health Sciences Authority (HSA), empowering Cuprina to legally manufacture and sell IVF media products.
Strategic Collaboration with Ferti-Craft
The newly equipped facility is designed to produce 14 distinct products—all essential components for successful fertilization processes. Cuprina’s partnership with Ferti-Craft not only involves manufacturing but also includes preparing required regulatory documentation for product registration. Together, they aim to gain HSA's approval for commercial sales by the late 2026 timeframe.
Production Plans and Market Expansion
Ferti-Craft plays a central role in ensuring that manufacturing processes align with international standards. The company will manage logistics and supply chains for raw materials, as well as leverage its expertise in human-assisted reproductive technologies to enhance product development. Initial sales efforts will focus on Singapore, with plans to expand into select ASEAN nations and other regions globally once the products are market-ready.
Leadership Insights on the New Facility
David Quek, CEO of Cuprina, expressed enthusiasm about this landmark project. He highlighted that the establishment of this pioneering IVF media facility in Singapore demonstrates their commitment to advancing reproductive technologies. Cuprina’s previous experience in creating ISO-compliant facilities has been invaluable for this new venture, ensuring timely production and high-quality outputs.
Ferti-Craft’s Perspective
Jai Thampi, co-founder of Ferti-Craft, echoed similar sentiments, noting the importance of collaboration with a reputable partner like Cuprina. Their combined efforts aim to create reliable IVF solutions that meet the rigorous standards necessary for the fertility treatment industry.
Growth Opportunities in the Art Market
The global Assisted Reproductive Technology (ART) market is expanding, estimated to reach $62.8 billion by 2032 according to industry reports. Factors contributing to this growth include an increase in the prevalence of infertility, societal acceptance of ART methods, and rising technology adoption rates. Cuprina’s new facility positions it favorably to tap into this growing market.
About Cuprina Holdings
Cuprina Holdings is a dedicated player in the biomedical and biotechnology sectors with a focus on developing and marketing solutions for chronic wounds and infertility. Their cutting-edge research fosters innovation in product development, aiming to provide effective healthcare solutions compliant with international standards.
Contact Information for Investors
Cuprina Holdings (Cayman) Limited welcomes inquiries from potential investors. For information regarding investor relations, individuals can connect via the following:
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08, Singapore 169201
Phone: +65 8512 7275
Email: ir@cuprina.com.sg
Frequently Asked Questions
What is the purpose of the new IVF media production facility?
The facility aims to produce IVF media products essential for fertilization, thus supporting advancements in reproductive health technology.
Who is collaborating with Cuprina Holdings on the project?
Ferti-Craft Pte Ltd. is partnering with Cuprina to produce and manage the IVF media products.
What certifications does the new facility have?
The facility has obtained ISO 13485 certification for medical device manufacturing and a dealer license from the Singapore HSA.
When is the expected launch of products from this new facility?
Commercial production is anticipated to commence in the fourth quarter of 2026.
What are the future expansion plans post-launch?
Initial sales will focus on Singapore, with future expansions planned into select ASEAN countries and globally as market demand grows.
